Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
Steigbigel
Roy T
RT
State University of New York at Stony Brook, The Rockefeller University, New York, New York, USA.
Cooper
David A
DA
Teppler
Hedy
H
Eron
Joseph J
JJ
Gatell
Jose M
JM
Kumar
Princy N
PN
Rockstroh
Jurgen K
JK
Schechter
Mauro
M
Katlama
Christine
C
Markowitz
Martin
M
Yeni
Patrick
P
Loutfy
Mona R
MR
Lazzarin
Adriano
A
Lennox
Jeffrey L
JL
Clotet
Bonaventura
B
Zhao
Jing
J
Wan
Hong
H
Rhodes
Rand R
RR
Strohmaier
Kim M
KM
Barnard
Richard J
RJ
Isaacs
Robin D
RD
Nguyen
Bach-Yen T
BY
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D019562:Viral Load
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium